| 2024-10 |
Enhanced production of recombinant coxsackievirus A16 using a serum-free HEK293A suspension culture system for bivalent enterovirus vaccine development |
Vaccine: X. 2024 Oct;20:Article number 100559. |
 |
| 2023-12 |
The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage |
Journal of Microbiology, Immunology and Infection. 2023 Dec;56(6):1121-1128. |
|
| 2023-03-24 |
Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system |
Virus Research. 2023 Mar 24;329:Article number 199101. |
|
| 2022-09-15 |
The uncoating of EV71 in mature late endosomes requires CD-M6PR |
Biology Open. 2022 Sep 15;11(9):Article number bio059469. |
|
| 2022-09-13 |
Separation and purification of highly infectious enterovirus A71 particles using a strong anion-exchange column |
Journal of Chromatography A. 2022 Sep 13;1680:Article number 463427. |
|
| 2022-05-08 |
Intranasal immunization with zika virus envelope domain III-flagellin fusion protein elicits systemic and mucosal immune responses and protection against subcutaneous and intravaginal virus challenges |
Pharmaceutics. 2022 May 8;14(5):Article number 1014. |
|
| 2022-01 |
Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies |
Expert Opinion on Drug Discovery. 2022 Jan;17(1):27-39. |
|
| 2019-11 |
Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development |
Vaccine. 2019 Nov;37(47):6933-6941. |
|
| 2019-04 |
Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development |
Antiviral Research. 2019 Apr;164:12-22. |
|
| 2019-03 |
Glycan-masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development |
Biotechnology and Bioengineering. 2019 Mar;116(3):598-609. |
|
| 2018-08-22 |
Recent development of enterovirus a vaccine candidates for the prevention of hand, foot, and mouth disease |
Expert Review of Vaccines. 2018 Aug 22;17(9):819-831. |
|
| 2018-08 |
Maternal immunization with a recombinant adenovirus-expressing fusion protein protects neonatal cotton rats from respiratory syncytia virus infection by transferring antibodies via breast milk and placenta |
Virology. 2018 Aug;521:181-189. |
|
| 2018-06-04 |
Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence [Erratum: Scientific Reports. 2018 Apr 27;8(1):Article number 6688.] |
Scientific Reports. 2018 Jun 4;8:Article number 8744. |
|
| 2018-05 |
Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture |
Vaccine. 2018 May;36(22):3134-3139. |
|
| 2018-04-27 |
Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence |
Scientific Reports. 2018 Apr 27;8(1):Article number 6688. |
|
| 2016-09 |
Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design |
Antiviral Research. 2016 Sep;133:110-118. |
|
| 2016-08 |
Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology |
Antiviral Research. 2016 Aug;132:225-232. |
|
| 2016-06 |
Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture |
Antiviral Research. 2016 Jun;130:27-35. |
|
| 2016-05 |
Immunological and biochemical characterizations of Coxsackievirus A6 and A10 viral particles |
Antiviral Research. 2016 May;129:58-66. |
|
| 2015-04 |
Recombinant adeno-vaccine expressing Enterovirus 71-like particles against hand, foot, and mouth disease |
PLoS Neglected Tropical Diseases. 2015 Apr;9(4):Article number e0003692. |
|
| 2015-03 |
Review of enterovirus 71 vaccines |
Clinical Infectious Diseases. 2015 Mar;60(5):797-803. |
|
| 2014-10 |
Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases |
Vaccine. 2014 Oct;32(47):6177-6182. |
|
| 2014-09-08 |
Long-term immunogenicity studies of formalin-inactivated Enterovirus 71 whole-virion vaccine in macaques |
PLoS ONE. 2014 Sep 8;9(9):Article number e106756. |
|
| 2014-08-27 |
Delivery of human EV71 receptors by adeno-associated virus increases EV71 infection-induced local inflammation in adult mice |
BioMed Research International. 2014 Aug 27;2014:Article number 878139. |
|
| 2014-07-30 |
Toll-like receptor 9-mediated protection of enterovirus 71 infection in mice is due to the release of danger-associated molecular patterns |
Journal of Virology. 2014 Jul 30;88(20):11658-11670. |
|
| 2014-06-11 |
Immunogenicity studies of bivalent Inactivated virions of EV71/CVA16 formulated with submicron emulsion systems |
Biomed Research International. 2014 Jun 11;2014:Article number 670506. |
|
| 2013-12 |
Monoclonal antibodies for diagnosis of enterovirus 71 |
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2013 Dec;32(6):386-394. |
|
| 2013-11-21 |
Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers |
PLoS ONE. 2013 Nov 21;8(11):Article number e79783. |
|
| 2013-11 |
Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV |
Human Vaccines and Immunotherapeutics. 2013 Nov ;9(11):2378-2385. |
|
| 2013-10-02 |
Heat Shock protein 90: Role in enterovirus 71 entry and assembly and potential target for therapy |
PLoS ONE. 2013 Oct 2;8(10):Article number e77133. |
|
| 2013-08 |
Caveolar endocytosis is required for human PSGL-1-mediated enterovirus 71 infection |
Journal of Virology. 2013 Aug;7(16):9064-9076. |
|
| 2013-07-30 |
Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice |
PLoS ONE. 2013 Jul 30;8(7):Article number e69858. |
|
| 2013-05 |
A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine |
Vaccine. 2013 May;31(20):2471-2476. |
|
| 2013-02-25 |
Human SCARB2 transgenic mice as an infectious animal model for Enterovirus 71 |
PLoS ONE. 2013 Feb 25;8(2):Article number e57591. |
|
| 2012-12 |
Production of EV71 vaccine candidates |
Human Vaccine Immunotherapy. 2012 Dec;8(12):1775-1783. |
|
| 2012-11-30 |
Immunological and biochemical characterization of Coxsackie Virus A16 viral particles |
PLoS ONE. 2012 Nov 30;7(11):Article number e49973. |
|
| 2012-09 |
Immunological evaluation and comparison of different EV71 vaccine candidates |
Clinical and Developmental Immunology. 2012 Sep;2012:Article ID 831282. |
|
| 2012-04 |
Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates |
PLoS ONE. 2012 Apr;7(4):Article number e34834. |
|
| 2012-01 |
Human SCARB2-Mediated entry and endocytosis of EV71 |
PLoS ONE. 2012 Jan;7(1):Article number e30507. |
|
| 2012-01 |
Selection and characterization of vaccine strain for Enterovirus 71 vaccine development |
Vaccine. 2012 Jan;30(4):703-711. |
|
| 2011-09 |
Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process |
Journal of Virological Methods. 2011 Sep;176(1-2):60-68. |
|
| 2011-06 |
Identification and characterization of a cross-neutralization epitope of Enterovirus 71 |
Vaccine. 2011 Jun;29(26):4362-4372. |
|
| 2011-05 |
Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system |
PLoS ONE. 2011 May;6(5):Article number e20005. |
|
| 2011-05 |
Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates |
Journal of Virological Methods. 2011 May;173(2):189-195. |
|
